Jefferies Initiates Coverage On Spyre Therapeutics with Buy Rating, Announces Price Target of $31
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Akash Tewari has initiated coverage on Spyre Therapeutics (NASDAQ:SYRE) with a Buy rating and set a price target of $31.
December 11, 2023 | 1:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Jefferies analyst Akash Tewari has initiated coverage on Spyre Therapeutics with a Buy rating and a price target of $31.
The initiation of coverage by Jefferies with a Buy rating and a price target significantly higher than the current trading price is likely to be viewed positively by investors. This could lead to increased investor confidence and a potential short-term increase in the stock price of Spyre Therapeutics.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100